Novo Nordisk to Acquire Akero Therapeutics for $4.7 Billion to Advance MASH Treatment Portfolio

Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics in a deal valued at $4.7 billion. The acquisition aims to strengthen Novo Nordisk’s portfolio by incorporating efruxifermin, an investigational therapy for metabolic dysfunction-associated steatohepatitis (MASH), also known as nonalcoholic steatohepatitis (NASH).

Efruxifermin is currently being studied as a potential treatment for MASH, a chronic liver condition characterized by fat buildup, inflammation, and fibrosis in the liver. The transaction highlights Novo Nordisk’s strategic focus on expanding its offerings in the field of metabolic diseases. Details regarding the timeline for finalizing the acquisition or further development plans for efruxifermin have not been disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 9, 2025

Author

Mark Chiang